Biotech upstart raises $10.5M for MRSA antibody

Hoping to thrive in a development arena long neglected by Big Pharma, Woburn, MA-based Excelimmune has raised $10.5 million in a Series B to fund its work on an antibody candidate targeting MRSA. The round was provided by a group of unnamed "high net worth" angel investors. "The continued support from investors underscores the significant potential of our unique HRPA approach to treating nosocomial infectious disease," said Quinton Zondervan, the CEO of Excelimmune. "In addition to doubling Excelimmune's size over the past year, this funding provides us with the capital required to enter the next stage of our product and technology development." Excelimmune release

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .